Owkin
Founded Year
2016Stage
Corporate Minority | AliveTotal Raised
$334.1MLast Raised
$80M | 2 yrs agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+155 points in the past 30 days
About Owkin
Owkin operates as an artificial intelligence (AI)-based biotechnology company. It utilizes AI to enhance the process of finding suitable treatments for patients. The company's main services include the use of AI to identify new treatments, accelerate clinical trials, and build diagnostic tools. It enables researchers in hospitals, universities, and the biopharmaceutical industry to understand how drug efficacy varies for the improvement of drug development. Its services primarily cater to the biopharmaceutical and academic research sectors. It was founded in 2016 and is based in New York, New York.
Loading...
ESPs containing Owkin
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The real-world data providers market offers a variety of value propositions to the pharmaceutical industry, drug labs, and healthcare organizations. It provides access to diverse patient populations, longitudinal real-world data, and patient-powered or EHR-powered controls that can replicate real-world scenarios. This can help shorten drug development timelines, reduce patient recruitment burdens …
Owkin named as Outperformer among 15 other companies, including Tempus, Syapse, and TriNetX.
Loading...
Research containing Owkin
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Owkin in 11 CB Insights research briefs, most recently on Aug 21, 2024.
Aug 21, 2024
The clinical trials tech market map
Oct 13, 2023
The open-source AI development market map
Aug 10, 2023
The oncology tech market map
Apr 11, 2022
The top 100 AI startups of 2021: Where are they now?
Expert Collections containing Owkin
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Owkin is included in 8 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,249 items
AI 100
400 items
Digital Health 50
300 items
The most promising digital health startups transforming the healthcare industry
Conference Exhibitors
5,302 items
Digital Health
11,109 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Precision Medicine Tech Market Map
160 items
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
Owkin Patents
Owkin has filed 13 patents.
The 3 most popular patent topics include:
- machine learning
- artificial neural networks
- classification algorithms
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
1/31/2020 | 10/15/2024 | Machine learning, Artificial neural networks, Image processing, Classification algorithms, Computer vision | Grant |
Application Date | 1/31/2020 |
|---|---|
Grant Date | 10/15/2024 |
Title | |
Related Topics | Machine learning, Artificial neural networks, Image processing, Classification algorithms, Computer vision |
Status | Grant |
Latest Owkin News
Oct 29, 2024
PARIS--(BUSINESS WIRE)--Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development, and diagnostics has announced MSIntuit® CRC v21, a next-generation AI solution. Aimed at transforming the detection and treatment of colorectal cancer (CRC), MSIntuit® CRC v2 will initially launch as an RUO version in the US on Roche’s navify® Digital Pathology enterprise software. MSIntuit® CRC v2 builds upon the success of the CE-IVD-certified MSIntu
Owkin Frequently Asked Questions (FAQ)
When was Owkin founded?
Owkin was founded in 2016.
Where is Owkin's headquarters?
Owkin's headquarters is located at 831 Broadway, New York.
What is Owkin's latest funding round?
Owkin's latest funding round is Corporate Minority.
How much did Owkin raise?
Owkin raised a total of $334.1M.
Who are the investors of Owkin?
Investors of Owkin include Bristol-Myers Squibb, Sanofi Ventures, EIT Health Gold Track, Plug and Play, Plug and Play Ventures and 15 more.
Who are Owkin's competitors?
Competitors of Owkin include Rhino Health, Aignostics, PictorLabs, biomy, Huma and 7 more.
Loading...
Compare Owkin to Competitors
PathAI provides artificial intelligence (AI)-powered research tools and services for pathology. It delivers the diagnosis and treatment of cancer by leveraging modern approaches in machine learning. The company offers biopharmacy lab services, clinical development services, drug and diagnostic development, and more. It was founded in 2016 and is based in Boston, Massachusetts.
Paige specializes in the development of digital pathology platforms and generative AI applications within the healthcare sector. The company offers a cloud-based platform that enhances pathologists' workflow, increases diagnostic confidence and productivity, and provides AI-driven precision in cancer diagnosis. Paige's technology also aids pharmaceutical companies in evaluating treatment options and designing new biomarkers for drug development. It was founded in 2017 and is based in New York, New York.
Insilico Medicine offers biotechnology software operating in pharmaceutical research and development. It offers services such as novel target discovery, generation of molecular structures with desired properties, and clinical trial analysis. Its services primarily cater to the healthcare industry, with a particular emphasis on the discovery and development of innovative drugs for a range of conditions, including cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. It was founded in 2014 and is based in Hong Kong.
Evidation focuses on harnessing real-world health data to measure and improve health outcomes. The company offers a digital health measurement and engagement platform that utilizes data science and machine learning to provide health guidance, treatments, and tools. Evidation primarily serves life sciences companies, government bodies, and academic institutions. It was founded in 2012 and is based in San Mateo, California.
Aitia focuses on the development and application of Causal AI and Digital Twins in the pharmaceutical industry. The company's main services include the discovery of drugs for neurodegenerative disorders, oncology, and immunology by revealing hidden biological mechanisms of diseases and creating Digital Twins. It is used to discover novel therapies and accelerate research and development in various diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, multiple myeloma, prostate cancer, and pancreatic cancer. It was founded in 2000 and is based in Cambridge, Massachusetts.
Apheris provides a collaborative data ecosystem platform. It enables multiple organizations to extract value from each other's decentralized data sets by allowing data providers and data consumers to collaborate in a technically and commercially viable way. It builds data solutions and unlocks new insights from distributed data of multiple parties without compromising on security and ownership. It serves industries such as healthcare, pharma, and manufacturing. It was founded in 2019 and is based in Berlin, Germany.
Loading...